GLP-1 Advertising in 2026: How to Run Compliant Meta & Google Ads Without Getting Banned

If you market a GLP-1 or weight-loss telehealth brand, you’re advertising in the single most scrutinized category on paid social. One flagged creative can cascade into a disabled ad account, and a disabled account at $200K/month spend is not a creative problem - it’s a company problem.

AdBoost Health is a Toronto-based agency that manages paid media exclusively for health, telehealth, and supplement brands, and compliance review is the first gate every creative passes through before a dollar of spend touches it. Here’s the playbook we run in 2026.

Platform ad policies change frequently - verify current requirements directly with Meta and Google before launch. This is practitioner guidance, not legal advice.

Why do GLP-1 ad accounts get banned?

Five triggers account for almost every GLP-1 account shutdown we’ve audited: drug-name copy, before/after imagery, personal-attributes violations, unsubstantiated outcome claims, and landing page mismatch.

1. Drug-name targeting in ad copy. Naming semaglutide or tirzepatide in an ad promoting your compounded or branded program reads as prescription drug promotion. Meta requires certification for that, and uncertified accounts get flagged fast.
2. Before/after imagery. Both Meta and Google treat weight-loss transformations as sensitive. Even “subtle” split-frame creative gets machine-flagged.
3. Personal attributes violations. Copy that implies knowledge of the viewer’s weight (“Struggling to lose those 30 lbs?”) violates Meta’s personal attributes policy - one of the most common and least understood triggers.
4. Unsubstantiated outcome claims. “Lose 15% of body weight” without clinical framing and disclaimers is a claims violation, even when the number comes from a real trial.
5. Landing page mismatch. The ad passes review, but the lander makes claims the ad didn’t. Platforms crawl your landers. This is the silent killer.

Here’s the same list as a working reference - what trips the classifier, and what to run instead:

Ban trigger	What flags it	Compliant alternative
Drug names in ad copy	Reads as prescription drug promotion without certification	Advertise the service: “talk to a licensed provider about medical weight-loss options”
Before/after imagery	Machine-flagged as sensitive transformation content - including split frames and “day 1 vs day 90” text overlays	Outcome data visualizations; patient stories built on energy and routine
Personal-attributes copy	Second-person references to the viewer’s weight or health status	Program-first framing: “a medical program built around your metabolism”
Unsubstantiated outcome claims	Outcome percentages with no clinical framing or disclaimer	Cited trial data with the source and disclaimer inside the creative file
Landing page mismatch	Platform crawlers find claims on the lander that the ad never made	Audit the lander against the same policy checklist as the ad

What does Meta actually require for GLP-1 ads in 2026?

Meta requires telehealth brands offering prescription products to hold LegitScript certification and apply for written permission before running prescription drug ads - without both, you’re limited to advertising the service (medical consultations, provider access), not the medication. That’s the load-bearing sentence in Meta’s health and pharmacy framework, and it sits inside the broader ad standards that govern personal attributes, sensational content, and claims. We keep a current breakdown of the policy line in our GLP-1 on Meta guide.

The service-versus-medication distinction is the entire game:

• Compliant: “Talk to a licensed provider about medical weight-loss options.”
• Non-compliant: “Get semaglutide delivered to your door for $199/month.”

Google runs a parallel system through its healthcare and medicines policy: pharmacies and telehealth providers need certification before drug-adjacent keywords and copy will serve, and unapproved drug terms trip disapprovals that accumulate into account-level trust damage. The enforcement styles differ - Google tends to disapprove ad by ad while Meta escalates to account-level action faster - but the direction is identical: certify first, or stay strictly on the service side of the line. The certification path is mapped step by step in our GLP-1 on Google guide.

How do you write GLP-1 ad creative that converts and passes review?

Build angles that are native to the constraints - sell the protocol, the provider, and the life after, never the drug itself. The mistake most agencies make is treating compliance as a legal filter applied after the creative process; that produces beige, dead ads. The teams that win in this category start from the constraint:

• Lead with the protocol, not the drug. “A medical program built around your metabolism” outperforms drug-name copy long-term anyway, because it frames a defensible brand instead of a commodity price war.
• Use clinician authority. Provider-led UGC (real MDs and NPs explaining how the program works) is the highest-performing compliant format we run. It converts because it borrows trust, and it passes because it’s educational.
• Sell the second-order outcome. Energy, confidence, bloodwork, longevity. You avoid the personal-attributes minefield entirely when the creative is about what life looks like after, not the viewer’s current body.
• Put claims on a compliance rail. Every stat gets a source, a disclaimer, and clinical framing - in the creative file itself, not just the lander. This is the same substantiation standard the FTC’s health products compliance guidance holds advertisers to, so building it into production isn’t overhead; it’s insurance against a second regulator.

Across AdBoost Health’s GLP-1 partner accounts, this system produces 20+ new creative variants per month, each reviewed against Meta, Google, and TikTok health policies before launch. That volume matters: compliant categories have higher creative fatigue because everyone’s fishing in the same constrained pond. If your creative engine can’t sustain that pace, read our breakdown of why health ad creative gets rejected and the system that scales. And the economics rhyme across the health vertical - supplement brands face the same constrained-claims, fatigue-prone auction, which is why the supplement brand CAC playbook reads as a companion piece to this one.

What should your landing page do differently?

Treat the lander as part of the ad, because platform review does. The compliant GLP-1 lander in 2026:

• States eligibility requirements and “prescription only if appropriate” language above the fold
• Shows real pricing with the consultation unbundled from medication
• Carries medical disclaimers and provider licensing information in crawlable HTML (not images)
• Avoids before/after galleries - use outcome data visualizations instead

We’ve seen accounts survive review sweeps purely because their landers were audit-clean while competitors’ weren’t. The inverse is also true: a clean ad pointing at a lander that promises what the ad carefully avoided is the single most common way “compliant” accounts still get flagged.

What do you do if your account is already banned?

Run a five-step recovery process: diagnose, fix, document, appeal - and only if the account is unrecoverable, rebuild with certification first. This is the sequence AdBoost Health runs when a partner arrives with a disabled account:

1. Diagnose the actual violation. Pull every rejection notice and policy citation from the account, then review the last 90 days of creative and the landing pages against the trigger table above. Most teams appeal blind; you can’t fix what you haven’t named.
2. Fix everything before appealing. Scrub drug names from live and paused ads, kill before/after assets, rewrite lander claims, add missing disclaimers. Appealing an un-fixed violation burns your credibility with review teams and makes every subsequent appeal slower.
3. Assemble the documentation. LegitScript certification, provider licenses, claim substantiation files, business verification. Appeals with documentation attached resolve materially faster than “we believe this was a mistake” tickets.
4. Submit one factual, specific appeal. State what was flagged, what you changed, and what the attached documentation proves. Resist the urge to re-submit the same appeal repeatedly - identical repeat appeals train the system toward auto-denial.
5. If the account is unrecoverable, rebuild properly. A new Business Manager, warmed gradually with non-health spend, certification completed before the first health ad runs. Not the growth-hack route of cycling fresh accounts - that triggers circumvention policies and ends with a permanent platform ban.

The better answer is to never be here. Compliance isn’t a tax on growth in this category; it’s the moat. Every brand that gets banned is a competitor removed from the auction, and the brands that build compliant creative systems inherit their traffic.

If you’re scaling a GLP-1 or weight-loss brand and want your account structure, creative, and landers audited against current policy - that’s literally the first thing we do on every strategy call. It’s free, takes 30 minutes, and you leave with a written plan either way.